These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26256101)

  • 21. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.
    Richardson C; Bargatze RF; Goodwin R; Mendelman PM
    Expert Rev Vaccines; 2013 Feb; 12(2):155-67. PubMed ID: 23414407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation and Protective Capacity of Virus-Specific CD8
    Tomov VT; Palko O; Lau CW; Pattekar A; Sun Y; Tacheva R; Bengsch B; Manne S; Cosma GL; Eisenlohr LC; Nice TJ; Virgin HW; Wherry EJ
    Immunity; 2017 Oct; 47(4):723-738.e5. PubMed ID: 29031786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.
    Blazevic V; Malm M; Vesikari T
    J Med Virol; 2015 Oct; 87(10):1656-61. PubMed ID: 25946711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noroviruses: epidemiology, immunity and prospects for prevention.
    Pringle K; Lopman B; Vega E; Vinje J; Parashar UD; Hall AJ
    Future Microbiol; 2015; 10(1):53-67. PubMed ID: 25598337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norovirus vaccines under development.
    Lucero Y; Vidal R; O'Ryan G M
    Vaccine; 2018 Aug; 36(36):5435-5441. PubMed ID: 28668568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody is critical for the clearance of murine norovirus infection.
    Chachu KA; Strong DW; LoBue AD; Wobus CE; Baric RS; Virgin HW
    J Virol; 2008 Jul; 82(13):6610-7. PubMed ID: 18417579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norovirus immunity and the great escape.
    Debbink K; Lindesmith LC; Donaldson EF; Baric RS
    PLoS Pathog; 2012; 8(10):e1002921. PubMed ID: 23093932
    [No Abstract]   [Full Text] [Related]  

  • 28. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection.
    Baldridge MT; Nice TJ; McCune BT; Yokoyama CC; Kambal A; Wheadon M; Diamond MS; Ivanova Y; Artyomov M; Virgin HW
    Science; 2015 Jan; 347(6219):266-9. PubMed ID: 25431490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations.
    Donaldson EF; Lindesmith LC; Lobue AD; Baric RS
    Immunol Rev; 2008 Oct; 225():190-211. PubMed ID: 18837783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norovirus vaccines: Correlates of protection, challenges and limitations.
    Melhem NM
    Hum Vaccin Immunother; 2016 Jul; 12(7):1653-69. PubMed ID: 26836766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the relationship between norovirus diversity and immunity.
    Ford-Siltz LA; Tohma K; Parra GI
    Gut Microbes; 2021; 13(1):1-13. PubMed ID: 33783322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary high-dose murine norovirus 1 infection fails to protect from secondary challenge with homologous virus.
    Liu G; Kahan SM; Jia Y; Karst SM
    J Virol; 2009 Jul; 83(13):6963-8. PubMed ID: 19403675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.
    Nice TJ; Baldridge MT; McCune BT; Norman JM; Lazear HM; Artyomov M; Diamond MS; Virgin HW
    Science; 2015 Jan; 347(6219):269-73. PubMed ID: 25431489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enteric bacteria promote human and mouse norovirus infection of B cells.
    Jones MK; Watanabe M; Zhu S; Graves CL; Keyes LR; Grau KR; Gonzalez-Hernandez MB; Iovine NM; Wobus CE; Vinjé J; Tibbetts SA; Wallet SM; Karst SM
    Science; 2014 Nov; 346(6210):755-9. PubMed ID: 25378626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013.
    Huhti L; Blazevic V; Puustinen L; Hemming M; Salminen M; Vesikari T
    Infect Genet Evol; 2014 Aug; 26():65-71. PubMed ID: 24837668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of immunity to norovirus gastroenteritis.
    Simmons K; Gambhir M; Leon J; Lopman B
    Emerg Infect Dis; 2013 Aug; 19(8):1260-7. PubMed ID: 23876612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic norovirus infection in primary immune deficiency disorders: an international case series.
    Rolfes MC; Sriaroon P; Dávila Saldaña BJ; Dvorak CC; Chapdelaine H; Ferdman RM; Chen K; Jolles S; Patel NC; Kim YJ; Tarrant TK; Martelius T; Seppanen M; Joshi AY
    Diagn Microbiol Infect Dis; 2019 Jan; 93(1):69-73. PubMed ID: 30174143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norovirus.
    Robilotti E; Deresinski S; Pinsky BA
    Clin Microbiol Rev; 2015 Jan; 28(1):134-64. PubMed ID: 25567225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and genetic diversity of noroviruses in adults with acute gastroenteritis in Beijing, China in 2008-2009.
    Tian G; Jin M; Li H; Li Q; Wang J; Duan ZJ
    J Med Virol; 2014 Jul; 86(7):1235-42. PubMed ID: 24523136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.